Is Cellebrite DI Ltd. overvalued or undervalued?

As of 14 November 2025, the valuation grade for Cellebrite DI Ltd. moved from fair to attractive, indicating a more favorable assessment of its stock. The company appears to be undervalued, particularly given its Price to Book Value of 10.89 and an EV to EBITDA ratio of 50.27, which suggest that the market may not be fully recognizing its potential despite the current loss-making status reflected in the P/E ratio being unavailable. Notably, its ROE stands at -53.38%, highlighting significant challenges in generating returns on equity.
In comparison to peers, Clearwater Analytics Holdings, Inc. shows a much more favorable P/E of 12.49 and an EV to EBITDA of 115.40, while Zeta Global Holdings Corp. presents a risky profile with a P/E of -120.85. This peer comparison underscores the relative risk associated with Cellebrite DI Ltd., yet its attractive valuation signals potential upside. Although specific return data is not available, the overall market sentiment and the company's recent performance suggest that it may be positioned for recovery, reinforcing the notion of its undervaluation.